Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | HTR1D | P28221 | 2/20 | 0.33 |
| ▸ | HTR1B | P28222 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.33 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.32 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4730537 | 0.91 | CYP1A1 (0.47) | CYP1A1CYP1B1 | |
| SCHEMBL18087240 | 0.91 | CXCR2 (0.35) | STSCA1CA2PPARGHTR1A | |
| SCHEMBL18002911 | 0.88 | EPAS1 (0.35) | STSCA1CA2PPARGHTR1A | |
| SCHEMBL18001992 | 0.88 | ALDH1A1 (0.37) | STSCA1CA2PPARGHTR1A | |
| SCHEMBL926505 | 0.85 | CA2 (0.41) | CA1CA2HTR1AHTR1DHTR1B | |
| SCHEMBL13168953 | 0.83 | AHR (0.43) | CA1CA2PPARGHTR1AHTR1D | |
| SCHEMBL2809078 | 0.82 | MAOA (0.57) | PPARGMAOAMAOBCYP1A1 | |
| SCHEMBL30036812 | 0.82 | MAOA (0.49) | CA1CA2PPARGMAOAMAOB | |
| SCHEMBL840975 | 0.80 | STS (0.60) | STSCA1CA2PPARGCXCR2 | |
| SCHEMBL19818371 | 0.80 | CXCR2 (0.31) | CXCR2CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3072873-B1 | VITAMIN D ANALOGUES OF PHARMACEUTICAL INTEREST | UNIV SANTIAGO COMPOSTELA (ES) | 2019-02-20 | — | — | EP | disclosed |
| US-9878045-B2 | Triorthogonal reagents for dual protein conjugation | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2018-01-30 | — | — | US | disclosed |
| US-9663429-B2 | Vitamin D analogues of pharmaceutical interest | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2017-05-30 | — | — | US | disclosed |
| US-9663429-B2 | Vitamin D analogues of pharmaceutical interest | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2017-05-30 | — | — | US | disclosed |
| US-9663429-B2 | Vitamin D analogues of pharmaceutical interest | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2017-05-30 | — | — | US | disclosed |
| US-20160297731-A1 | VITAMIN D ANALOGUES OF PHARMACEUTICAL INTEREST | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2016-10-13 | — | — | US | disclosed |
| US-20160297731-A1 | VITAMIN D ANALOGUES OF PHARMACEUTICAL INTEREST | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2016-10-13 | — | — | US | disclosed |
| US-20160297731-A1 | VITAMIN D ANALOGUES OF PHARMACEUTICAL INTEREST | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2016-10-13 | — | — | US | disclosed |
| EP-3072873-A1 | VITAMIN D ANALOGUES OF PHARMACEUTICAL INTEREST | Universidade De Santiago De Compostela (ES) | 2016-09-28 | — | — | EP | disclosed |
| EP-3072873-A1 | VITAMIN D ANALOGUES OF PHARMACEUTICAL INTEREST | Universidade De Santiago De Compostela (ES) | 2016-09-28 | — | — | EP | disclosed |
| US-20160271261-A1 | TRIORTHOGONAL REAGENTS FOR DUAL PROTEIN CONJUGATION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2016-09-22 | — | — | US | disclosed |
| WO-2015075291-A1 | VITAMIN D ANALOGUES OF PHARMACEUTICAL INTEREST | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015057863-A1 | TRIORTHOGONAL REAGENTS FOR DUAL PROTEIN CONJUGATION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297731-A1 | VITAMIN D ANALOGUES OF PHARMACEUTICAL INTEREST | CYP24A1, VDR, CYP2R1 | STS 1633/4885CA1 1347/4885CA2 216/4885 |
| US-20160271261-A1 | TRIORTHOGONAL REAGENTS FOR DUAL PROTEIN CONJUGATION | FNTA, FNTB, GNPAT | STS 682/4885CA1 4338/4885CA2 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.